Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Operating Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Operating Leases for 7 consecutive years, with $67.0 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 7.44% to $67.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67.0 million through Dec 2025, down 7.44% year-over-year, with the annual reading at $67.0 million for FY2025, 7.44% down from the prior year.
  • Operating Leases for Q4 2025 was $67.0 million at Kymera Therapeutics, down from $68.4 million in the prior quarter.
  • The five-year high for Operating Leases was $77.0 million in Q4 2023, with the low at $12.1 million in Q4 2022.
  • Average Operating Leases over 5 years is $48.3 million, with a median of $67.7 million recorded in 2025.
  • The sharpest move saw Operating Leases dropped 8.15% in 2022, then skyrocketed 534.18% in 2023.
  • Over 5 years, Operating Leases stood at $13.2 million in 2021, then fell by 8.15% to $12.1 million in 2022, then surged by 534.18% to $77.0 million in 2023, then decreased by 5.98% to $72.4 million in 2024, then decreased by 7.44% to $67.0 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $67.0 million, $68.4 million, and $69.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.